Research graph
References from SITE-SPECIFIC FUNCTIONALIZATION OF PROTEINS AND THEIR APPLICATIONS TO THERAPEUTIC ANTIBODIES. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s0022-1759(96)00173-1
10.1016/s0022-1759(96)00173-1 · External reference
10.1021/bc200556n
10.1021/bc200556n · External reference
Chemoenzymatic labeling of protein C-termini for positive selection of C-terminal peptides
10.1021/cb200164h · 2011 · External reference
Straightforward thiol-mediated protein labelling with DTPA: Synthesis of a highly active 111In-annexin A5-DTPA tracer
10.1186/2191-219x-2-17 · 2012 · External reference
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
10.1038/nbt.2108 · 2012 · External reference
Site-specific PEGylation of native disulfide bonds in therapeutic proteins
10.1038/nchembio786 · 2006 · External reference
Emerging awareness of the critical roles of S-phosphocysteine and selenophosphate in biological systems
1994 · External reference
10.1146/annurev.bi.65.070196.001325
10.1146/annurev.bi.65.070196.001325 · External reference
Cysteine S-glycosylation, a new post-translational modification found in glycopeptide bacteriocins
10.1016/j.febslet.2011.01.023 · 2011 · External reference
10.1039/c1sc00185j
10.1039/c1sc00185j · External reference
10.1021/bc00014a008
10.1021/bc00014a008 · External reference
10.1039/c3cc42261e
10.1039/c3cc42261e · External reference
N-Terminal dual protein functionalization by strain-promoted alkyne-nitrone cycloaddition
10.1039/c3ob00043e · 2013 · External reference
10.1126/science.7973629
10.1126/science.7973629 · External reference
Site-specific protein labeling by intein-mediated protein ligation
10.1007/978-1-61737-967-3_6 · 2011 · External reference
10.1039/c0sc00562b
10.1039/c0sc00562b · External reference
10.1002/anie.200600368
10.1002/anie.200600368 · External reference
10.1021/ja802495w
10.1021/ja802495w · External reference
10.1021/ja408868a
10.1021/ja408868a · External reference
10.1021/ja208009r
10.1021/ja208009r · External reference
[Incorporation of structural analogues of amino acids in bacterial proteins]
10.1016/0006-3002(56)90207-4 · 1956 · External reference
Amino acid analog incorporation into bacterial proteins
10.1016/0006-3002(59)90230-6 · 1959 · External reference
10.1016/s0014-5793(98)00489-x
10.1016/s0014-5793(98)00489-x · External reference
10.1073/pnas.012583299
10.1073/pnas.012583299 · External reference
10.1002/anie.200900942
10.1002/anie.200900942 · External reference
Site-specific modification of Candida antarctica lipase B via residue-specific incorporation of a non-canonical amino acid
10.1021/bc800019v · 2008 · External reference
Substrate specificity is determined by amino acid binding pocket size in Escherichia coli phenylalanyl-tRNA synthetase
10.1021/bi00189a013 · 1994 · External reference
Relaxing the substrate specificity of an aminoacyl-tRNA synthetase allows in vitro and in vivo synthesis of proteins containing unnatural amino acids
10.1016/0014-5793(95)00408-2 · 1995 · External reference
Attenuation of the editing activity of the Escherichia coli leucyl-tRNA synthetase allows incorporation of novel amino acids into proteins in vivo
10.1021/bi026130x · 2002 · External reference
10.1016/0022-2836(91)90740-w
10.1016/0022-2836(91)90740-w · External reference
10.1126/science.1057718
10.1126/science.1057718 · External reference
10.1126/science.2649980
10.1126/science.2649980 · External reference
Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide
10.1021/ja00202a052 · 1989 · External reference
10.1126/science.7716551
10.1126/science.7716551 · External reference
Progress toward the evolution of an organism with an expanded genetic code
10.1073/pnas.96.9.4780 · 1999 · External reference
10.1016/j.jmb.2009.10.030
10.1016/j.jmb.2009.10.030 · External reference
10.1146/annurev.biochem.052308.105824
10.1146/annurev.biochem.052308.105824 · External reference
10.1021/ja9614225
10.1021/ja9614225 · External reference
10.1073/pnas.0510817103
10.1073/pnas.0510817103 · External reference
10.4061/2011/207691
10.4061/2011/207691 · External reference
10.1038/nchembio834
10.1038/nchembio834 · External reference
10.1074/jbc.271.10.5289
10.1074/jbc.271.10.5289 · External reference
Dual fatty acylation of p59(Fyn) is required for association with the T cell receptor zeta chain through phosphotyrosine-Src homology domain-2 interactions
10.1083/jcb.145.2.377 · 1999 · External reference
N-Myristoyl transferase-mediated protein labelling in vivo
10.1039/b803258k · 2008 · External reference
10.1073/pnas.0403413101
10.1073/pnas.0403413101 · External reference
Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues
10.1096/fasebj.5.15.1683845 · 1991 · External reference
10.1002/bit.24622
10.1002/bit.24622 · External reference
Transglutaminase-catalyzed site-specific conjugation of small-molecule probes to proteins in vitro and on the surface of living cells
10.1021/ja0604111 · 2006 · External reference
10.1038/nchembio878
10.1038/nchembio878 · External reference
10.1073/pnas.0807820106
10.1073/pnas.0807820106 · External reference
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
10.1038/nprot.2012.045 · 2012 · External reference
10.1038/nbt765
10.1038/nbt765 · External reference
Phosphonate analogues of triacylglycerols are potent inhibitors of lipase
10.1016/0005-2760(95)00145-3 · 1995 · External reference
Histidine 289 is essential for hydrolysis of the alkyl-enzyme intermediate of haloalkane dehalogenase
10.1074/jbc.270.18.10405 · 1995 · External reference
Directed evolution of O6-alkylguanine-DNA alkyltransferase for applications in protein labeling
10.1093/protein/gzl014 · 2006 · External reference
10.1073/pnas.0705201104
10.1073/pnas.0705201104 · External reference
The HaloTag: a novel technology for cell imaging and protein analysis
2007 · External reference
10.1016/j.chembiol.2008.01.007
10.1016/j.chembiol.2008.01.007 · External reference
10.1038/nmeth735
10.1038/nmeth735 · External reference
10.1038/nbt1355
10.1038/nbt1355 · External reference
10.1021/ja208090p
10.1021/ja208090p · External reference
An engineered aryl azide ligase for site-specific mapping of protein-protein interactions through photo-cross-linking
10.1002/anie.200802088 · 2008 · External reference
Structure-guided engineering of a Pacific Blue fluorophore ligase for specific protein imaging in living cells
10.1021/bi201037r · 2011 · External reference
10.1021/ja209325n
10.1021/ja209325n · External reference
10.1016/s1074-5521(96)90181-7
10.1016/s1074-5521(96)90181-7 · External reference
10.1074/jbc.270.42.24658
10.1074/jbc.270.42.24658 · External reference
A novel function of yeast fatty acid synthase
10.1046/j.1432-1327.2000.01282.x · 2000 · External reference
10.1021/ja045127t
10.1021/ja045127t · External reference
10.1073/pnas.0507705102
10.1073/pnas.0507705102 · External reference
10.1021/cb700054k
10.1021/cb700054k · External reference
10.1126/science.285.5428.760
10.1126/science.285.5428.760 · External reference
10.1128/mmbr.70.1.192-221.2006
10.1128/mmbr.70.1.192-221.2006 · External reference
10.1002/anie.201008267
10.1002/anie.201008267 · External reference
Substrate filtering by the active site crossover loop in UCHL3 revealed by sortagging and gain-of-function mutations
10.1074/jbc.m807172200 · 2009 · External reference
Site-specific N- and C-terminal labeling of a single polypeptide using sortases of different specificity
10.1021/ja902681k · 2009 · External reference
10.1074/jbc.m901752200
10.1074/jbc.m901752200 · External reference
10.1039/c1cc13322e
10.1039/c1cc13322e · External reference
10.1073/pnas.1016863108
10.1073/pnas.1016863108 · External reference
Protein-Protein Fusion Catalyzed by Sortase A
10.1371/journal.pone.0018342 · 2011 · External reference
10.1073/pnas.1101046108
10.1073/pnas.1101046108 · External reference
Protein splicing elements: inteins and exteins–a definition of terms and recommended nomenclature
10.1093/nar/22.7.1125 · 1994 · External reference
10.1006/meth.2001.1187
10.1006/meth.2001.1187 · External reference
Site-specific modification of ED-B-targeting antibody using intein-fusion technology
10.1186/1472-6750-11-76 · 2011 · External reference
10.1021/bc0341728
10.1021/bc0341728 · External reference
Intein-mediated in vitro synthesis of lipidated Ras proteins
10.1039/b511736d · 2006 · External reference
Efficient, chemoselective synthesis of immunomicelles using single-domain antibodies with a C-terminal thioester
10.1186/1472-6750-9-66 · 2009 · External reference
10.1073/pnas.95.12.6705
10.1073/pnas.95.12.6705 · External reference
10.1016/j.bmcl.2005.03.079
10.1016/j.bmcl.2005.03.079 · External reference
Cell-permeable small molecule probes for site-specific labeling of proteins
2003 · External reference
Purification of proteins fused to either the amino or carboxy terminus of the Mycobacterium xenopi gyrase A intein
10.2144/99271st04 · 1999 · External reference
10.1007/s11084-011-9243-4
10.1007/s11084-011-9243-4 · External reference
10.1038/nbt1252
10.1038/nbt1252 · External reference
10.1093/glycob/12.4.43r
10.1093/glycob/12.4.43r · External reference
O-Glycosylation of Nuclear and Cytosolic Proteins: DYNAMIC INTERPLAY BETWEEN O-GlcNAc ANDO-PHOSPHATE
10.1074/jbc.r000010200 · 2000 · External reference
10.1002/jps.21504
10.1002/jps.21504 · External reference
10.1126/science.287.5460.2007
10.1126/science.287.5460.2007 · External reference
10.1038/nprot.2007.422
10.1038/nprot.2007.422 · External reference
Direct in-gel fluorescence detection and cellular imaging of O-GlcNAc-modified proteins
10.1021/ja8030467 · 2008 · External reference
Site-specific Labeling of Antibody N-glycans using a Click Chemistry-mediated Chemoenzymatic Approach
2012 · External reference
Roles of glycans and glycopeptides in immune system and immune-related diseases
10.2174/092986706776360897 · 2006 · External reference
10.1021/np068054v
10.1021/np068054v · External reference
10.1038/nrd2399
10.1038/nrd2399 · External reference
10.1517/17425247.2.1.29
10.1517/17425247.2.1.29 · External reference
10.1016/j.drudis.2006.08.005
10.1016/j.drudis.2006.08.005 · External reference
Modifications of therapeutic proteins: challenges and prospects
10.1007/s10616-007-9075-2 · 2007 · External reference
Measurement of renal function during drug development
10.1046/j.1365-2125.2002.01625.x · 2002 · External reference
10.1007/s00253-007-1142-2
10.1007/s00253-007-1142-2 · External reference
Fab antibody fragments: some applications in clinical toxicology
10.2165/00002018-200427140-00004 · 2004 · External reference
Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy
2010 · External reference
10.1007/978-1-4614-7107-3_8
10.1007/978-1-4614-7107-3_8 · 2013 · External reference
The impact of PEGylation on biological therapies
2008 · External reference
Branched and Linear Poly(Ethylene Glycol): Influence of the Polymer Structure on Enzymological, Pharmacokinetic, and Immunological Properties of Protein Conjugates
10.1177/088391159701200303 · 1997 · External reference
Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation
10.1006/cyto.2001.0936 · 2001 · External reference
Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol)
10.1021/bc300066a · 2012 · External reference
Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins
1983 · External reference
10.1002/cncr.22739
10.1002/cncr.22739 · External reference
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
2006 · External reference
10.1002/anie.200902672
10.1002/anie.200902672 · External reference
Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Review article
1994 · External reference
10.1016/j.tips.2009.04.007
10.1016/j.tips.2009.04.007 · External reference
Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents
10.1002/ibd.20225 · 2007 · External reference
10.1038/nrd3365
10.1038/nrd3365 · External reference
The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody
10.1038/bjc.1994.459 · 1994 · External reference
Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification
10.1007/s11912-007-0006-3 · 2007 · External reference
10.1021/cr9001066
10.1021/cr9001066 · External reference
Factors determining antibody distribution in tumors
2008 · External reference
Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors
1989 · External reference
10.1073/pnas.92.19.8999
10.1073/pnas.92.19.8999 · External reference
Affinity and avidity in antibody-based tumor targeting
2009 · External reference
10.1038/nri2155
10.1038/nri2155 · External reference
10.1002/eji.1830260327
10.1002/eji.1830260327 · External reference
The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor
10.1073/pnas.93.11.5512 · 1996 · External reference
Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn
10.1046/j.1365-2567.1996.d01-775.x · 1996 · External reference
Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys
2012 · External reference
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges
10.4331/wjbc.v3.i4.73 · 2012 · External reference
10.1016/j.jconrel.2012.01.026
10.1016/j.jconrel.2012.01.026 · External reference
10.3390/toxins3070848
10.3390/toxins3070848 · External reference
10.1021/ar700108g
10.1021/ar700108g · External reference
10.1056/nejmra043186
10.1056/nejmra043186 · External reference
10.1158/0008-5472.can-08-1776
10.1158/0008-5472.can-08-1776 · External reference
10.1200/jco.2012.44.9694
10.1200/jco.2012.44.9694 · External reference
10.1007/s00280-011-1817-3
10.1007/s00280-011-1817-3 · External reference
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
10.1182/blood-2003-01-0039 · 2003 · External reference
10.1158/1078-0432.ccr-04-0789
10.1158/1078-0432.ccr-04-0789 · External reference
10.1021/ja303904e
10.1021/ja303904e · External reference
10.1073/pnas.1211023109
10.1073/pnas.1211023109 · External reference
10.1021/ja309505c
10.1021/ja309505c · External reference
10.1177/00912700122012751
10.1177/00912700122012751 · External reference
10.4161/mabs.1.6.10015 · Admitted local publication
10.1038/314628a0
10.1038/314628a0 · External reference
Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies
10.1084/jem.160.6.1686 · 1984 · External reference
10.1038/316354a0
10.1038/316354a0 · External reference
10.1158/1078-0432.ccr-05-1855
10.1158/1078-0432.ccr-05-1855 · External reference
10.1084/jem.175.1.217
10.1084/jem.175.1.217 · External reference
10.1038/nbt.2621
10.1038/nbt.2621 · External reference
Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer
2008 · External reference
Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies
10.4049/jimmunol.155.1.219 · 1995 · External reference
10.4161/mabs.2.2.11221 · Admitted local publication
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
10.1111/j.1365-2249.2009.03992.x · 2009 · External reference
10.1016/j.jmb.2011.01.011
10.1016/j.jmb.2011.01.011 · External reference
Gold nanoparticles in biology and medicine: recent advances and prospects
10.32607/20758251-2011-3-2-34-55 · 2011 · External reference
Immunoliposomes for cancer therapy
2006 · External reference
Biodegradable polymersomes as a basis for artificial cells: encapsulation, release and targeting
10.1016/j.jconrel.2004.09.026 · 2005 · External reference
10.1021/la052445c
10.1021/la052445c · External reference
10.1016/j.biomaterials.2011.08.036
10.1016/j.biomaterials.2011.08.036 · External reference
Nanobody-Functionalized Polymersomes for Tumor-Vessel Targeting
10.1002/mabi.201300039 · 2013 · External reference
10.1016/j.addr.2010.04.009
10.1016/j.addr.2010.04.009 · External reference
10.1146/annurev-bioeng-071811-150124
10.1146/annurev-bioeng-071811-150124 · External reference
10.1016/j.ccr.2007.03.012
10.1016/j.ccr.2007.03.012 · External reference
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
10.1038/mt.2013.32 · 2013 · External reference
A Phase I Study of MM-302, a HER2-targeted Liposomal Doxorubicin
2012 · External reference
10.1016/s1470-2045(12)70476-x
10.1016/s1470-2045(12)70476-x · External reference
10.1093/annonc/mdh092
10.1093/annonc/mdh092 · External reference
